Discovery and evaluation of protein biomarkers as a signature of wellness in late-stage cancer patients in early phase clinical trials
Authors
Geary, BethanyPeat, Erin
Dransfield, Sarah
Cook, Natalie
Thistlethwaite, Fiona C
Graham, Donna
Carter, Louise
Hughes, Andrew M
Krebs, Matthew G
Whetton, Anthony D
Affiliation
Stoller Biomarker Discovery Centre, Faculty of Biology, Medicine and Health, University of Manchester, ManchesterIssue Date
2021
Metadata
Show full item recordAbstract
TARGET (tumour characterisation to guide experimental targeted therapy) is a cancer precision medicine programme focused on molecular characterisation of patients entering early phase clinical trials. Performance status (PS) measures a patient's ability to perform a variety of activities. However, the quality of present algorithms to assess PS is limited and based on qualitative clinician assessment. Plasma samples from patients enrolled into TARGET were analysed using the mass spectrometry (MS) technique: sequential window acquisition of all theoretical fragment ion spectra (SWATH)-MS. SWATH-MS was used on a discovery cohort of 55 patients to differentiate patients into either a good or poor prognosis by creation of a Wellness Score (WS) that showed stronger prediction of overall survival (p = 0.000551) compared to PS (p = 0.001). WS was then tested against a validation cohort of 77 patients showing significant (p = 0.000451) prediction of overall survival. WS in both sets had receiver operating characteristic curve area under the curve (AUC) values of 0.76 (p = 0.002) and 0.67 (p = 0.011): AUC of PS was 0.70 (p = 0.117) and 0.55 (p = 0.548). These signatures can now be evaluated further in larger patient populations to assess their utility in a clinical setting.Citation
Geary B, Peat E, Dransfield S, Cook N, Thistlethwaite F, Graham D, et al. Discovery and Evaluation of Protein Biomarkers as a Signature of Wellness in Late-Stage Cancer Patients in Early Phase Clinical Trials. Cancers. 2021 May 18;13(10):2443.Journal
CancersDOI
10.3390/cancers13102443PubMed ID
34069985Additional Links
https://dx.doi.org/10.3390/cancers13102443Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.3390/cancers13102443
Scopus Count
Collections
Related articles
- Applying 'Sequential Windowed Acquisition of All Theoretical Fragment Ion Mass Spectra' (SWATH) for systematic toxicological analysis with liquid chromatography-high-resolution tandem mass spectrometry.
- Authors: Arnhard K, Gottschall A, Pitterl F, Oberacher H
- Issue date: 2015 Jan
- Comprehensive MS/MS profiling by UHPLC-ESI-QTOF-MS/MS using SWATH data-independent acquisition for the study of platelet lipidomes in coronary artery disease.
- Authors: Schlotterbeck J, Chatterjee M, Gawaz M, Lämmerhofer M
- Issue date: 2019 Jan 10
- Optimization of Acquisition and Data-Processing Parameters for Improved Proteomic Quantification by Sequential Window Acquisition of All Theoretical Fragment Ion Mass Spectrometry.
- Authors: Li S, Cao Q, Xiao W, Guo Y, Yang Y, Duan X, Shui W
- Issue date: 2017 Feb 3
- SWATH mass spectrometry as a tool for quantitative profiling of the matrisome.
- Authors: Krasny L, Bland P, Kogata N, Wai P, Howard BA, Natrajan RC, Huang PH
- Issue date: 2018 Oct 30
- Comparison of information-dependent acquisition, SWATH, and MS(All) techniques in metabolite identification study employing ultrahigh-performance liquid chromatography-quadrupole time-of-flight mass spectrometry.
- Authors: Zhu X, Chen Y, Subramanian R
- Issue date: 2014 Jan 21